<DOC>
	<DOC>NCT00584584</DOC>
	<brief_summary>This study will investigate whether a single dose QAX576 (an interleukin-13 monoclonal antibody) gives protection against a model of hayfever</brief_summary>
	<brief_title>An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>History of allergic rhinitis. Respiratory disease other than mild intermittent asthma. Received immunotherapy in past 3 years. History of clinically significant drug allergy. History of clinical schistosomiasis or travel within 6 months prior to or following study to an area with endemic schistosomiasis. History of exposure to human therapeutic antibodies, immunoglobulins or other plasma products. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Allergic rhinitis, adults, monoclonal antibody, interleukin-13.</keyword>
</DOC>